Article 1: Solving Poor Solubility

Unveiling the Layers of Solubility

The details

Poor solubility in drug candidates is a multifaceted challenge with important trade-offs to consider. For such a pivotal issue, the intricacies of drug solubility are vital, yet they often go unnoticed or under-appreciated.

Background

Approximately 70% of new compounds emerging from modern drug discovery pipelines display poor aqueous solubility. This means they cannot be adequately absorbed after oral intake without some form of enhancement to achieve the necessary bioavailability.
Illustrated sketch of lab tubes used in SeraNovo formulation development

Solubilizing an Insoluble Molecule: “Aqueous solubility” is a general term, and understanding its individual components, as listed below, is beneficial. Together, they comprise what is termed “apparent solubility.”

1. Crystalline Solubility

This refers to the concentration of an Active Pharmaceutical Ingredient (API) that can be solubilized when the API is in its crystalline form (its lowest energy state).

2. Amorphous Solubility

This relates to the concentration of an API that can be solubilized when the API is in its amorphous state (a higher energy form). Typically, it’s approximately 5-10 times greater than the crystalline solubility.

3. Colloidal Phase

When the concentration of an API surpasses its amorphous solubility, droplets rich in amorphous drug form, typically measuring between 100-500 nm in size.

Graph comparing apparent solubility over time with and without formulation, showing supersaturation effect by Seranovo

It’s crucial to break down the apparent solubility values we encounter into each of their individual contributing solubilities:

Crystalline, Amorphous, and Colloidal

When solubility exceeds the amorphous threshold, a phenomenon known as Liquid-Liquid Phase Separation (LLPS) takes place, leading to the formation of a colloidal phase.

In practical terms, this implies that the API will spontaneously separate from the aqueous phase to form API-rich colloids, typically 100-500nm in size.

It’s worth noting that these formed colloids are not genuinely solubilised. While they usually don’t contribute directly to absorption, they act as an amorphous reservoir. This reservoir is in equilibrium with the amorphous API, ensuring sustained high absorption rates.

The occurrence of LLPS is significant as it represents the peak of thermodynamic activity—a term denoting the API’s propensity to permeate across epithelial cells for absorption.

Diagram showing human gastrointestinal drug absorption conditions for API solubility and bioavailability analysis
Bar chart showing API distribution in monophasic and biphasic phases under gastric and intestinal conditions
As evident from these figures, the primary question isn’t just ‘how do I increase the solubility of the drug‘ since that tackles only about 1% of the challenge. The more pressing query is, ‘given that up to 99% of the administered dose isn’t immediately available for absorption, how can it be temporarily stabilized to facilitate absorption over time?’

SeraNovo offers a suite of technologies specifically designed to address this pertinent question.

Alternatively, you can arrange a conversation with our technical experts within 24 hours

Share the Post:

Interested to know more?

If you have any questions or want to schedule a meeting fill in the form
SeraNovo scientist holding pharmaceutical capsule for innovative drug formulation